MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis
Sign Up to like & getrecommendations! Published in 2022 at "BMC Gastroenterology"
DOI: 10.1186/s12876-022-02101-7
Abstract: Background Malignant ascites is a manifestation of end stage events in a variety of cancers and is associated with significant morbidity. Epigenetic modulators play a key role in cancer initiation and progression, among which histone… read more here.
Keywords: cancer; class; malignant ascites; hdac ... See more keywords